DiaSorin receives FDA clearance for two tests; stock pre-market at EUR 78.34
Published on 10/14/2026 at 08:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA clearance and market availability
- DiaSorin received FDA clearance for two Parvovirus B19 tests on October 13, 2026.
- DiaSorin stock trades pre-market at EUR 78.34 at 8:12 a.m. CEST at Lang & Schwarz on October 14, 2026.
- The two tests were already available in the United States on October 13, 2026.
DiaSorin received U.S. Food and Drug Administration clearance for two automated Parvovirus B19 serology tests on October 13, 2026, according to Alliance News. DiaSorin stock was at EUR 78.34 pre-market at Lang & Schwarz at 8:12 a.m. CEST on October 14, 2026.
Pre-market price
The Lang & Schwarz quote showed a bid of EUR 78.22 and an ask of EUR 78.46. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of DiaSorin stock.
FDA clearance for Parvovirus B19 tests
The authorization covers LIAISON Biotrin Parvovirus B19 IgM Plus and IgG Plus, which are based on DiaSorin's LIAISON XL immunoassay system. The tests are designed to detect IgM and IgG antibodies against Parvovirus B19 and were already available in the United States on October 13, 2026, Alliance News reported. The company said the automated tests can provide same-day results and support faster diagnosis and treatment management.
Market context: Market report FTSE MIB.
